Literature DB >> 2541133

Quantitation of poliovirus antigens in inactivated viral vaccines by enzyme-linked immunosorbent assay using animal sera and monoclonal antibodies.

C Singer1, F Knauert, G Bushar, M Klutch, R Lundquist, G V Quinnan.   

Abstract

Recent advances in methods for the manufacture of inactivated poliovirus vaccines have resulted in increased vaccine immunogenicity. In conjunction with this capability it is important to have available highly sensitive and quantitative potency assays. The potential suitability of enzyme-linked immunoassay (ELISA) was evaluated using animal sera with neutralizing antibodies or neutralizing monoclonal antibodies for antigen detection in potency tests. The monoclonal antibodies developed, which bound D antigen but not C antigen, were neutralizing unless relatively weakly reactive. Those that bound C antigen only were non-neutralizing. Those that bound both C and D antigens were sometimes neutralizing. D-specific and D/C-specific neutralizing monoclonal antibodies against type-2 poliovirus protected mice on passive immunization against paralytic disease and death from the MEF strain virus. Potency measurements by ELISA using either D-specific neutralizing monoclonal antibodies or type-specific goat sera for antigen detection were sensitive and precise. Tests using C-specific monoclonal antibodies for antigen detection indicated that increased C antigen content may result in falsely elevated reactivities of animal sera with some vaccines. Monoclonal antibodies may be useful ELISA reagents for IPV potency testing.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2541133     DOI: 10.1016/0092-1157(89)90004-8

Source DB:  PubMed          Journal:  J Biol Stand        ISSN: 0092-1157


  9 in total

1.  Effect of formaldehyde inactivation on poliovirus.

Authors:  Thomas Wilton; Glynis Dunn; David Eastwood; Philip D Minor; Javier Martin
Journal:  J Virol       Date:  2014-08-06       Impact factor: 5.103

2.  Thin silk fibroin films as a dried format for temperature stabilization of inactivated polio vaccine.

Authors:  Jordan A Stinson; Carter R Palmer; David P Miller; Adrian B Li; Kandice Lightner; Heather Jost; William C Weldon; M Steven Oberste; Jonathan A Kluge; Kathryn M Kosuda
Journal:  Vaccine       Date:  2020-01-17       Impact factor: 3.641

3.  High resolution identity testing of inactivated poliovirus vaccines.

Authors:  Edward T Mee; Philip D Minor; Javier Martin
Journal:  Vaccine       Date:  2015-06-03       Impact factor: 3.641

4.  New Strains Intended for the Production of Inactivated Polio Vaccine at Low-Containment After Eradication.

Authors:  Sarah Knowlson; John Burlison; Elaine Giles; Helen Fox; Andrew J Macadam; Philip D Minor
Journal:  PLoS Pathog       Date:  2015-12-31       Impact factor: 6.823

5.  Genetically Thermo-Stabilised, Immunogenic Poliovirus Empty Capsids; a Strategy for Non-replicating Vaccines.

Authors:  Helen Fox; Sarah Knowlson; Philip D Minor; Andrew J Macadam
Journal:  PLoS Pathog       Date:  2017-01-19       Impact factor: 6.823

6.  Plant-made polio type 3 stabilized VLPs-a candidate synthetic polio vaccine.

Authors:  Johanna Marsian; Helen Fox; Mohammad W Bahar; Abhay Kotecha; Elizabeth E Fry; David I Stuart; Andrew J Macadam; David J Rowlands; George P Lomonossoff
Journal:  Nat Commun       Date:  2017-08-15       Impact factor: 14.919

7.  Comparative Molecular Biology Approaches for the Production of Poliovirus Virus-Like Particles Using Pichia pastoris.

Authors:  Lee Sherry; Keith Grehan; Joseph S Snowden; Michael L Knight; Oluwapelumi O Adeyemi; David J Rowlands; Nicola J Stonehouse
Journal:  mSphere       Date:  2020-03-11       Impact factor: 4.389

8.  Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines.

Authors:  Mohammad W Bahar; Claudine Porta; Helen Fox; Andrew J Macadam; Elizabeth E Fry; David I Stuart
Journal:  NPJ Vaccines       Date:  2021-01-08       Impact factor: 7.344

9.  Multiplex PCR-based titration (MPBT) assay for determination of infectious titers of the three Sabin strains of live poliovirus vaccine.

Authors:  Hasmik Manukyan; Elvira Rodionova; Tatiana Zagorodnyaya; Tsai-Lien Lin; Konstantin Chumakov; Majid Laassri
Journal:  Virol J       Date:  2019-10-28       Impact factor: 4.099

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.